Developments In T Cell Based Cancer Immunotherapies
Developments In T Cell Based Cancer Immunotherapies Book in PDF, ePub and Kindle version is available to download in english. Read online anytime anywhere directly from your device. Click on the download button below to get a free pdf file of Developments In T Cell Based Cancer Immunotherapies book. This book definitely worth reading, it is an incredibly well-written.
Author : Paolo A. Ascierto,David F. Stroncek,Ena Wang Publisher : Humana Press Page : 305 pages File Size : 41,8 Mb Release : 2015-11-26 Category : Medical ISBN : 9783319211671
Developments in T Cell Based Cancer Immunotherapies by Paolo A. Ascierto,David F. Stroncek,Ena Wang Pdf
This volume illustrates the salient aspects of cancer biology relevant to the successful implementation of immunotherapy. Topics include enhancement of antigen-specific immune responses by anti-cancer vaccines, modulation of the function of T cells within the tumor microenvironment, and the effects of genetic, epigenetic, developmental, and environmental determinants on T cell function. Other topics covered include the ex vivo expansion of T or other immune cells and their genetic modification or reprogramming to increase their ability to survive and expand when adoptively transferred back to the patients. Specific attention is devoted to the genetic manipulation of T cells through the introduction of re-directed T cell receptors, chimeric antibody receptors, and other genetic manipulation aimed at improving their effectiveness as anti-cancer agents. Furthermore, the revolutionary role of checkpoint inhibitors and their potential in combination with other immunotherapeutic approaches or with standard chemo and radiation therapy are extensively discussed.
Current Immunotherapeutic Strategies in Cancer by Matthias Theobald Pdf
This book offers a comprehensive review of recent advances in cancer immunotherapy, and explores the value and limitations of the most effective current therapeutic strategies and emerging treatment modalities. It discusses in detail the successes achieved using monoclonal antibodies (mAbs), including developments with regard to conjugated mAbs and also bispecific mAbs as novel treatment options for leukemia and solid tumors. It also examines the advances toward personalized immunotherapy, focusing on the effectiveness of adoptive cell therapy using genetically engineered T cells with tumor-associated antigen-specific T-cell receptors and chimeric antigen receptors, as well as the role of tailored vaccines based on the patient’s cancer mutanome. Further, it describes the impressive therapeutic results recently achieved with checkpoint inhibitors, and analyzes novel strategies to modulate the immunosuppressive tumor microenvironment. Written by leading international experts and providing up-to-date information on emerging strategies, such as oncolytic virus-based therapy, epigenetic therapy, and combination therapy, the book appeals to all those with an interest in immunotherapy as it comes of age.
Author : Mary L. Disis Publisher : Springer Science & Business Media Page : 516 pages File Size : 41,7 Mb Release : 2007-10-28 Category : Medical ISBN : 9781597450119
Expert bench and clinical scientists join forces to concurrently review both the state-of-the-art in tumor immunology and its clinical translation into promising practical treatments. The authors explain in each chapter the scientific basis behind such therapeutic agents as monoclonal antibodies, cytokines, vaccines, and T-cells, and illustrate their clinical manipulation to combat cancer. Additional chapters address statistical analysis-both of clinical trials and assay evaluations-methods for the discovery of antigens, adoptive T cell therapy, and adaptive and innate immunity. The challenges in clinical trial design, the need for biomarkers of response-such as novel imaging techniques and immunologic monitoring-and the new advances and directions in cancer immunotherapy are also fully examined.
Cancer Immunotherapy Principles and Practice, Second Edition by Lisa H. Butterfield, PhD,Howard L. Kaufman, MD, FACS,Francesco M. Marincola, MD, FACS Pdf
Thoroughly updated to reflect major advances in the field of immuno-oncology, this second edition of Cancer Immunotherapy Principles and Practice, from the Society for Immunotherapy of Cancer (SITC), remains the definitive resource for information on tumor immunology and cancer immunotherapy treatments. An essential reference for both novice and experienced cancer researchers, oncologists, and related practitioners alike, the book not only guides readers through the fundamental scientific principles of the field all the way to translational and practical clinical applications for treating and managing oncologic disease, but also provides a comprehensive understanding of the regulatory processes that support the safe and effective delivery of immunotherapy to patients with cancer. The expanded and updated second edition now spans 68 chapters, including 12 new chapters, covering major topics and innovations that have shaped the rapid development of immunotherapy and its ascension into the standard of care as first-line treatment for a growing number of disease settings. New to this edition are chapters with deeper insight into our understanding of cancer genomics and determinants of response, immunogenic cell death, cancer and stromal cell-intrinsic pathways of immune resistance, cancer immune exclusion, adoptive cell therapy, metabolomics, tumor mutation burden, immunotherapy in combination with radiation therapy, synthetic biology, and more. Complete with detailed illustrations, tables, and key points for targeted reference, Cancer Immunotherapy Principles and Practice, Second Edition is the most comprehensive and authoritative resource for scientists and clinicians looking to expand their knowledge base of this dynamic field. Key Features: Offers key insights and perspectives on cancer immunology and immunotherapy treatments from renowned experts in the field Covers the basic principles and science behind cancer immunotherapy and tumor immunology Includes treatment strategies for a vast array of available immunotherapy classes and agents, such as cytokine therapies, oncolytic viruses, cancer vaccines, CAR T therapies, and combination immunotherapies Provides essential information on FDA-approved immunotherapies, including clinical management and outcome data related to response rates, risks, and toxicities Discusses special considerations for immunotherapy in the context of specific disease settings, including skin cancers, genitourinary cancers, gastrointestinal cancers, hepatocellular carcinomas, gynecologic malignancies, breast cancers, lung cancers, head and neck cancers, brain tumors, sarcomas, pediatric cancers, and treatments combined with radiation therapy Clarifies the complex regulatory aspects behind the development and approval of immunotherapy drugs
National Academies of Sciences, Engineering, and Medicine,Health and Medicine Division,Board on Health Care Services,National Cancer Policy Forum
Author : National Academies of Sciences, Engineering, and Medicine,Health and Medicine Division,Board on Health Care Services,National Cancer Policy Forum Publisher : National Academies Press Page : 89 pages File Size : 44,6 Mb Release : 2019-10-05 Category : Medical ISBN : 9780309490863
Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors by National Academies of Sciences, Engineering, and Medicine,Health and Medicine Division,Board on Health Care Services,National Cancer Policy Forum Pdf
In recent years, significant progress has been made in the clinical development and use of various types of cancer immunotherapy, all of which rely on the immune system to fight cancer. The majority of new cancer drug applications submitted to the Food and Drug Administration (FDA) are for immunotherapies or combinations involving immunotherapies. One type of immunotherapy is an immune checkpoint inhibitor. Cells in the human body have proteins that regulate the immune system response to foreign invaders (e.g., cancer cells, microorganisms). However, cancer cells can coopt these "checkpoint" proteins and thwart the immune system's ability to recognize and attack cancer cells. To help promote an immune response to cancer, researchers have developed immune checkpoint inhibitors that enable T-cells to recognize cancer cells as foreign and to prevent deactivation of an immune system response. To examine the challenges and opportunities to develop combination cancer therapies that include immune checkpoint inhibitors, the National Cancer Policy Forum held a workshop on July 16â€"17, 2018, in Washington, DC. This workshop convened stakeholders with a broad range of expertise, including cancer researchers, clinicians, patient advocates, and representatives from industry, academia, and government. This publication summarizes the presentations and discussions from the workshop.
Cancer Immunotherapy Principles and Practice by Lisa H. Butterfield, PhD,Howard L. Kaufman, MD, FACS,Francesco M. Marincola, MD, FACS Pdf
Cancer Immunotherapy Principles and Practice, from the Society of Immunotherapy of Cancer (SITC), is the authoritative reference on cancer immunobiology and the immunotherapy treatments that harness the immune system to combat malignant disease. Featuring five sections and over 50 chapters covering the Basic Principles of Tumor Immunology, Cancer Immunotherapy Targets and Classes, Immune Function in Cancer Patients, Disease Specific Treatments and Outcomes, and Regulatory Aspects of Cancer Immunotherapy, this book covers all major topics that have shaped the development of immunotherapy and propelled it to its current place at the forefront of cancer treatment innovation. This volume is a comprehensive resource for oncologists and fellows, immunologists, cancer researchers, and related practitioners seeking understanding of the basic science and clinical applications of cancer immunotherapy. As well as presenting the evidence for immune-based cancer treatment, it positions immunotherapy in the context of other available cancer treatments and provides data on response rates, risks, and toxicities across a variety of diseases. Filled with detailed tables, and instructive illustrations, as well as key points for quick reference, Cancer Immunotherapy Principles and Practice simplifies a challenging and dynamic subject. Key Features: Clearly summarizes the basic principles and research supporting cancer immunotherapy clinical translation Contains expert guidance and treatment strategies for all immunotherapy classes and agents, including cell-based therapies, monoclonal antibodies, cytokine therapies, checkpoint inhibitors, oncolytic viruses, adjuvant approaches, and treatment combinations Includes expert perspectives from leading authorities in the field Provides information on all FDA-approved immunotherapies, including clinical management and outcome data Discusses clinical aspects of immunotherapy for individual cancer types, including melanoma and other skin cancers, lung cancers, gynecologic cancers, gastrointestinal cancers, hematologic cancers, genitourinary cancers, head and neck cancers, sarcomas, brain and other CNS cancers, breast cancer, and pediatric malignancies. Explains regulatory aspects behind the development and approval of immunotherapy drugs Includes Online Access to the Digital Book
Joseph D. Rosenblatt,Eckhard R. Podack,Glen N. Barber,Augusto Ochoa
Author : Joseph D. Rosenblatt,Eckhard R. Podack,Glen N. Barber,Augusto Ochoa Publisher : Springer Science & Business Media Page : 371 pages File Size : 54,7 Mb Release : 2013-10-25 Category : Medical ISBN : 9781461488095
Advances in Tumor Immunology and Immunotherapy by Joseph D. Rosenblatt,Eckhard R. Podack,Glen N. Barber,Augusto Ochoa Pdf
Recent advances in understanding of fundamental immunology have created new insights into the dynamic interactions between tumors and the immune system. This includes new understanding of T- and B-cell interaction, immune inhibitory mechanisms including the biology of T regulatory cells, myeloid suppressor cells, and dendritic cell subsets. Enhanced understanding of mechanisms underlying T-cell anergy such as arginine deprivation, immunosuppressive cytokines, defective innate and interferon response pathways, and NKG2D downregulation have all provided new insight into suppression of anti-tumor immunity and tumor evasion. In addition to emerging understanding of tumor evasion, new immune targets such as CTLA4 blockade, NK stimulatory receptors, manipulation of the antigen processing and presentation, cytokine and costimulatory responses all provide new possibilities for enhancing anti-tumor immunity even in tumors previously felt to be resistant to immune attack. Several of these strategies have already been realized in the clinic. The volume will explore evolving paradigms in antigen presentation, dendritic cell biology, the innate response and immunosuppressive mechanisms, and emerging strategies for manipulation of the immune system for therapeutic benefit that have realized success in neuroblastoma, leukemia, melanoma, lung cancer, and allogeneic transplantation. Early successes as well as failures will be highlighted to provide a snapshot of the state of clinical immunotherapy with an eye to future possibilities such as combination therapies, adoptive T-cell transfer, and the retargeting of immune cells via T-cell receptor engineering.
Laurence J. N. Cooper,Elizabeth A. Mittendorf,Judy Moyes,Sabitha Prabhakaran
Author : Laurence J. N. Cooper,Elizabeth A. Mittendorf,Judy Moyes,Sabitha Prabhakaran Publisher : John Wiley & Sons Page : 312 pages File Size : 47,8 Mb Release : 2018-02-08 Category : Medical ISBN : 9781118684504
Immunotherapy in Translational Cancer Research by Laurence J. N. Cooper,Elizabeth A. Mittendorf,Judy Moyes,Sabitha Prabhakaran Pdf
A guide to state-of-the-art cancer immunotherapy in translational cancer research A volume in the Translational Oncology series, Immunotherapy in Translational Cancer Research explores the recent developments in the role that immunotherapy plays in the treatment of a wide range of cancers. The editors present key concepts, illustrative examples, and suggest alternative strategies in order to achieve individualized targeted therapy. Comprehensive in scope, Immunotherapy in Translational Cancer Research reviews the relevant history, current state, and the future of burgeoning cancer-fighting therapies. The book also includes critical information on drug development, clinical trials, and governmental resources and regulatory issues. Each chapter is created to feature: development of the immunotherapy; challenges that have been overcome in order to scale up and undertake clinical trials; and clinical experience and application of research. This authoritative volume is edited by a team of noted experts from MD Anderson Cancer Center, the world’s foremost cancer research and care center and: Offers a comprehensive presentation of state-of-the-art cancer immunotherapy research that accelerates the pace of clinical cancer care Filled with the concepts, examples, and approaches for developing individualized therapy Explores the breath of treatments that reflect the complexity of the immune system itself Includes contributions from a panel international experts in the field of immunotherapy Designed for physicians, medical students, scientists, pharmaceutical executives, public health and public policy government leaders and community oncologists, this essential resource offers a guide to the bidirectional interaction between laboratory and clinic immunotherapy cancer research.
Experimental and Applied Immunotherapy by Jeffrey Medin,Daniel Fowler Pdf
Immunotherapy is now recognized as an essential component of treatment for a wide variety of cancers. It is an interdisciplinary field that is critically dependent upon an improved understanding of a vast network of cross-regulatory cellular populations and a diversity of molecular effectors; it is a leading example of translational medicine with a favorable concept-to-clinical-trial timeframe of just a few years. There are many established immunotherapies already in existence, but there are exciting new cancer immunotherapies just on the horizon, which are likely to be more potent, less toxic and more cost effective than many therapies currently in use. Experimental and Applied Immunotherapy is a state-of-the-art text offering a roadmap leading to the creation of these future cancer-fighting immunotherapies. It includes essays by leading researchers that cover a wide variety of topics including T cell and non-T cell therapy, monoclonal antibody therapy, dendritic cell-based cancer vaccines, mesenchymal stromal cells, negative regulators in cancer immunology and immunotherapy, non-cellular aspects of cancer immunotherapy, the combining of cancer vaccines with conventional therapies, the combining of oncolytic viruses with cancer immunotherapy, transplantation, and more. The field of immunotherapy holds great promise that will soon come to fruition if creative investigators can bridge seemingly disparate disciplines, such as T cell therapy, gene therapy, and transplantation therapy. This text is a vital tool in the building of that bridge.
National Academies of Sciences, Engineering, and Medicine,Health and Medicine Division,Board on Health Care Services,National Cancer Policy Forum
Author : National Academies of Sciences, Engineering, and Medicine,Health and Medicine Division,Board on Health Care Services,National Cancer Policy Forum Publisher : National Academies Press Page : 135 pages File Size : 45,5 Mb Release : 2016-12-10 Category : Medical ISBN : 9780309442329
Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer Treatment by National Academies of Sciences, Engineering, and Medicine,Health and Medicine Division,Board on Health Care Services,National Cancer Policy Forum Pdf
Immunotherapy is a form of cancer therapy that harnesses the body's immune system to destroy cancer cells. In recent years, immunotherapies have been developed for several cancers, including advanced melanoma, lung cancer, and kidney cancer. In some patients with metastatic cancers who have not responded well to other treatments, immunotherapy treatment has resulted in complete and durable responses. Given these promising findings, it is hoped that continued immunotherapy research and development will produce better cancer treatments that improve patient outcomes. With this promise, however, there is also recognition that the clinical and biological landscape for immunotherapies is novel and not yet well understood. For example, adverse events with immunotherapy treatment are quite different from those experienced with other types of cancer therapy. Similarly, immunotherapy dosing, therapeutic responses, and response time lines are also markedly different from other cancer therapies. To examine these challenges and explore strategies to overcome them, the National Academies of Sciences, Engineering, and Medicine held a workshop in February and March of 2016. This report summarizes the presentations and discussions from the workshop.
Cellular Therapy Of Cancer: Development Of Gene Therapy Based Approaches by Robert E Hawkins Pdf
Cancer research has progressed enormously in recent years. This review volume will address recent findings in the area of T-cell therapy for cancer, including use of tumour infiltrating lymphocytes (TILs) as a therapy for melanoma, choice of target antigens, advances in engineered receptors, methods of gene transfer to T cells, review of cell processing methods and clinical trial design. Written by leadings scientists in the field, this up-to-date review on cancer research will be an important reference source to the researchers and healthcare professionals in the field.
The Heterogeneity of Cancer Metabolism by Anne Le Pdf
This open access volume will introduce recent discoveries in cancer metabolism since the publication of the first edition in 2018, providing readers with an up-to-date understanding of developments in the field. Genetic alterations in cancer, in addition to being the fundamental drivers of tumorigenesis, can give rise to a variety of metabolic adaptations that allow cancer cells to survive and proliferate in diverse tumor microenvironments. This metabolic flexibility is different from normal cellular metabolic processes and leads to heterogeneity in cancer metabolism within the same cancer type or even within the same tumor. In this book, the authors delve into the complexity and diversity of cancer metabolism and highlight how understanding the heterogeneity of cancer metabolism is fundamental to the development of effective metabolism-based therapeutic strategies for cancer treatment. Deciphering how cancer cells utilize various nutrient resources will enable clinicians and researchers to pair specific chemotherapeutic agents with patients who are most likely to respond with positive outcomes, allowing for more cost-effective and personalized cancer treatment. This book has four major parts. Part one will cover the basic metabolism of cancer cells, followed by a discussion of the heterogeneity of cancer metabolism in part two. Part three addresses the relationship between cancer cells and cancer-associated fibroblasts, and the new part four will explore the metabolic interplay between cancer and other diseases. This new section makes the book unique from other texts currently available on the market. The second edition will be useful for cancer metabolism researchers, cancer biologists, epidemiologists, physicians, health care professionals in related disciplines, policymakers, marketing and economic strategists, among others. It may also be used in courses such as intro to cancer metabolism, cancer biology, and related biochemistry courses for undergraduate and graduate students.
Gene and Cellular Immunotherapy for Cancer by Armin Ghobadi,John F. DiPersio Pdf
Clinical and preclinical exploration of gene and cellular immunotherapy have seen rapid growth and interest with the development and approval of five Chimeric Antigen Receptor T-cell (CAR-T) products for lymphoma and myeloma and one Bispecific T-Cell Engager (BiTE) for acute lymphoblastic leukemia (ALL). These advances have dramatically improved the management of patients with relapsed refractory lymphoma, myeloma and leukemia. Gene and Cellular Immunotherapy for Cancer offers readers a comprehensive review of current cellular and gene-based immunotherapies. Divided into eighteen cohesive chapters, this book provides an in-depth and detailed look into cellular-based immunotherapies including CAR-T, TCR-T, TIL, Viral CTLs, NK cells in addition to T/NK cell engagers, focusing on their historical perspectives, biology, development and manufacturing, toxicities and more. Edited by two leading experts on gene and cellular immunotherapy, the book will feature chapters written by a diverse collection of recognized and up-and-coming experts and researchers in the field, providing oncologists, immunologists, researchers and clinical and basic science trainees with a bench to bedside view of the latest developments in the field.
Cancer Immunotherapy Meets Oncology by Cedrik Michael Britten,Sebastian Kreiter,Mustafa Diken,Hans-Georg Rammensee Pdf
This book provides a comprehensive update on the state of the art in cancer immunology, which has rapidly evolved from a field of clinical research into an established discipline of oncology. The key recent developments in immuno-oncology are all covered, from the ever-changing immunological and regulatory frameworks to the most promising therapeutic concepts. Themes include combination therapies and personalized medicine, as well as identification of biomarkers to guide the clinical development of new approaches and to pinpoint the optimal treatment for each patient. The book acknowledges the continuing dynamic nature of the field as reflected in the development of next-generation immunotherapies that are already in clinical testing. Cancer Immunotherapy Meets Oncology is dedicated to the lifetime achievements of Christoph Huber, founder and chair of the Association for Cancer Immunotherapy (CIMT). It is also a tribute to those researchers and clinicians who are striving to develop novel diagnostics and tailored immunotherapies for the benefit of cancer patients.